Veraxa Biotech Holding AG VRXA
Annual
Quarterly
No annual revenue total was found in Veraxa Biotech Holding AG's SEC filings.
Veraxa Biotech Holding AG (VRXA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRXA (Nasdaq), VRXAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zurich
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079109
- Former names
- Veraxa Biotech Holding AG (until Aug 13, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Aug 24, 2026 | Aug 24, 2026 |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
All 56 Veraxa Biotech Holding AG SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.